Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells

Most ovarian cancer patients are chemosensitive initially, but finally relapse with acquired chemoresistance. Multidrug‐resistance is the extremely terrible situation. The mechanism for the acquired chemoresistance of ovarian cancer patients is still not clear. LncRNAs have been recognized as the im...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cellular physiology 2018-06, Vol.233 (6), p.5034-5043
Main Authors: Xu, Juan, Wu, Jiacong, Fu, Chenyang, Teng, Fang, Liu, Siyu, Dai, Chencheng, Shen, Rong, Jia, Xuemei
Format: Article
Language:English
Subjects:
Antineoplastic Agents - pharmacology
ATP Binding Cassette Transporter, Subfamily B - genetics
ATP Binding Cassette Transporter, Subfamily B - metabolism
ATP Binding Cassette Transporter, Subfamily G, Member 2 - genetics
ATP Binding Cassette Transporter, Subfamily G, Member 2 - metabolism
Biological activity
Biomarkers, Tumor - genetics
Biotechnology
Cancer
Cell Line, Tumor
Chemoresistance
Chemotherapy
Cisplatin
Cisplatin - pharmacology
Colon
Colon cancer
Colonic Neoplasms - drug therapy
Colonic Neoplasms - genetics
Colonic Neoplasms - metabolism
Colonic Neoplasms - pathology
Computational Biology
Databases, Genetic
Drug Resistance, Multiple - genetics
Drug Resistance, Neoplasm - genetics
Epirubicin
Epirubicin - pharmacology
Female
Gene expression
Gene Expression Profiling - methods
Gene Expression Regulation, Neoplastic
Gene Regulatory Networks
Humans
LncRNA
mRNA
Multidrug resistance
Multidrug Resistance-Associated Proteins - genetics
Multidrug Resistance-Associated Proteins - metabolism
Multidrug resistant organisms
Neoplasm Proteins - genetics
Neoplasm Proteins - metabolism
Ovarian cancer
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - genetics
Ovarian Neoplasms - metabolism
Ovarian Neoplasms - pathology
paclitaxel
Paclitaxel - pharmacology
Patients
RNA, Long Noncoding - genetics
RNA, Long Noncoding - metabolism
Tumor cell lines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Most ovarian cancer patients are chemosensitive initially, but finally relapse with acquired chemoresistance. Multidrug‐resistance is the extremely terrible situation. The mechanism for the acquired chemoresistance of ovarian cancer patients is still not clear. LncRNAs have been recognized as the important regulator of a variety of biological processes, including the multidrug‐resistant process. Here, we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2780/PTX which is also cross resistant to the cisplatin and epirubicin. Through integrating the published data with the cisplatin resistant lncRNAs in ovarian cancer cell line or ovarian cancer patients, 5 up‐regulated and 21 down‐regulated lncRNAs are considered as the multidrug‐resistant lncRNAs. By real‐time PCR analysis, we confirmed the 5 up‐regulated and 4 down‐regulated multidrug resistant lncRNAs were similarly changed in both the multidrug resistant ovarian cancer cell lines and the multidrug resistant colon cancer cell lines. Furthermore, we conducted the lncRNA‐mRNA co‐expression network to predict the potential multidrug resistant lncRNAs’ targets. Interestingly, the multidrug resistant genes ABCB1, ABCB4, ABCC3, and ABCG2 are all co‐expressed with lncRNA CTD‐2589M5.4. Our results provide the valuable information for the understanding of the lncRNA function in the multidrug resistant process. We carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2780/PTX which is also cross resistant to the cisplatin and epirubicin. Finally, five up‐regulated and four down‐regulated multidrug resistant lncRNAs was confirmed to be consistently changed in both the multidrug resistant ovarian cancer cell line and colon cancer cell line.
ISSN:0021-9541
1097-4652
DOI:10.1002/jcp.26369